Stoke Therapeutics Inc
$ 35.86
2.31%
14 Apr - close price
- Market Cap 2,121,147,000 USD
- Current Price $ 35.86
- High / Low $ 36.79 / 34.95
- Stock P/E N/A
- Book Value 5.98
- EPS -0.12
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.02 %
- 52 Week High 40.22
- 52 Week Low 7.34
About
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases in the United States. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$45.10
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-11 | 2025-11-04 | 2025-08-12 | 2025-05-05 | 2025-03-24 | 2024-11-05 | 2024-08-07 | 2024-05-06 | 2024-03-25 | 2023-11-07 | 2023-08-07 | 2023-05-04 |
| Reported EPS | -0.97 | -0.65 | -0.4 | 1.9 | -0.18 | -0.4691 | -0.46 | -0.57 | -0.6 | -0.55 | -0.69 | -0.53 |
| Estimated EPS | -0.713 | -0.58 | -0.5 | -0.0905 | -0.5302 | -0.53 | -0.56 | -0.61 | -0.63 | -0.63 | -0.64 | -0.7 |
| Surprise | -0.257 | -0.07 | 0.1 | 1.9905 | 0.3502 | 0.0609 | 0.1 | 0.04 | 0.03 | 0.08 | -0.05 | 0.17 |
| Surprise Percentage | -36.0449% | -12.069% | 20% | 2199.4475% | 66.0505% | 11.4906% | 17.8571% | 6.5574% | 4.7619% | 12.6984% | -7.8125% | 24.2857% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.8 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: STOK
2026-04-14 22:39:58
Stoke Therapeutics' (STOK) Zorevunersen has demonstrated sustained efficacy and cognitive improvements in Dravet syndrome, alongside strong long-term safety data. The company plans to complete phase III trials by Q2 2026, with regulatory approval anticipated in late 2027. This positive data and a broad market opportunity underpin the commercial strategy for Zorevunersen.
2026-04-14 08:09:54
Baillie Gifford & Co. has acquired a new stake in Stoke Therapeutics (NASDAQ:STOK), purchasing 246,900 shares valued at approximately $7.84 million. This move establishes Baillie Gifford & Co. as holding about 0.43% of the company's stock. Analysts generally rate STOK as a "Moderate Buy" with an average price target of $41.83, despite recent insider selling activities.
2026-04-09 20:09:39
Stoke Therapeutics appointed G. Clare Kahn, Ph.D., as chair of its R&D Committee, signaling a reinforced focus on late-stage pipeline execution, especially for its Phase 3 zorevunersen trial. Kahn brings significant regulatory and drug development experience which could impact how Stoke manages trial complexity and FDA feedback. While this strengthens the execution narrative, investors should be aware of the risk that regulators might not grant an accelerated approval.
2026-04-09 19:40:05
Stoke Therapeutics, a biotechnology company focused on RNA medicine, announced that its CEO, Ian F. Smith, will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 3:00 p.m. ET. The company's lead investigational medicine, zorevunersen, is being developed as a potential disease-modifying treatment for Dravet syndrome. A live webcast of the presentation will be available on the Investors & News section of Stoke’s website.
2026-04-09 04:10:19
Biogen and Stoke Therapeutics will present new clinical data for zorevunersen, an investigational treatment for Dravet syndrome, at the 36th International Epilepsy Congress. The data from open-label extension studies show durable seizure reductions and improvements in cognition and behavior over three years, supporting its potential as a disease-modifying therapy. Zorevunersen is currently in a global pivotal Phase 3 study (EMPEROR) to further evaluate its efficacy, safety, and tolerability in children with Dravet syndrome.
2026-04-08 23:10:09
Stoke Therapeutics announced that its CEO, Ian F. Smith, will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 3:00 p.m. ET. The company is a biotechnology firm focused on RNA medicine, with its lead investigational drug, zorevunersen, in development for Dravet syndrome. A webcast of the presentation will be available on Stoke’s investor relations website.
